Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy (Q, N,C,F)* Laboratories,  India, on July 28, 2008 announced that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the United States.

Omeprazole 40 mg is for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common side effects of Prilosec are headache, diarrhea and abdominal pain. Prilosec-40 mg had sales in the U.S market of USD 204.2 million.

Shares of the company gained Rs 12.95, or 2.69%, to trade at Rs 494.2. The total volume of shares traded was 616,580 at the BSE (11.57 a.m., Monday).